Treatment of febrile neutropenic patients with cancer who require hospitalization: A prospective randomized study comparing imipenem and cefepime

Cancer

Volumn 98, Issue 5, 2003, Pages 1039-1047

  Raad, Issam I ^a   Escalante, Carmen ^a   Hachero, Ray Y ^a   Hanna, Hend A ^a   Husni, Rola ^a   Afif, Claude ^a   Boktour, Maha R ^a   Whimbey, Estella E ^a   Kontoyiannis, Dimitrios ^a   Jacobson, Kalen ^a   Kantarjian, Hagop ^a   Levett, L Martin ^a   Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer patients; Cefepime; Febrile neutropenia; Imipenem

Indexed keywords

AMIKACIN; CEFEPIME; IMIPENEM; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SEIZURE; SUPERINFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CEPHALOSPORINS; FEMALE; FEVER; HOSPITALIZATION; HUMANS; IMIPENEM; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN;

EID: 0041386234     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11613     Document Type: Article

References (37)

1. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061-1065.
2. Bodey GP. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital. Rev Infect Dis. 1989;11:S1582-S1590.
3. Schimpff SC. Fever and neutropenia: an historical perspective. In: Rolston KV, Rubenstein EB, editors. Textbook of febrile neutropenia. London: Martin Dunitz Ltd., 2001:1-26.
4. Viscoli C, Van der Auwere P, Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother. 1988;21:149-156.
5. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490-494.
6. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis. 1999;29:494-502.
7. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1201-1207.
8. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551-573.
9. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
10. Raad II, Abi-Said D, Rolston KV, et al. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer. 1998;82:2449-2458.
11. Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992;152:283-291.
12. Eggimann P, Glauser MP, Aoun M, et al. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother. 1993;32:151-163.
13. Rolston KV, New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29:515-521.
14. Hughes WT, Pizzo PA, Wade JC, et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis. 1992;15:S206-S215.
15. Bodey GP, Alvarez ME, Jones GP, et al. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother. 1986;30:211-214.
16. Noorby SR, Vandercam BB, Louie T, et al. Imipenem-cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis. 1987;52:65-78.
17. Liang R, Yung R, Chau PY, et al. Imipenem/cilastatin as initial therapy for febrile neutropenic patients. J Antimicrob Chemother. 1988;22:765-770.
18. Bucaneve G, Menichetti F, Minotti V, et al. Ceftriaxone versus imipenem/cilastatin as empirical monotherapy for infections in cancer patients. Chemotherapy. 1989;35(Suppl): 10-15.
19. Hauer C, Urban C, Slavc I, et al. Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia. Pediatr Hematol Oncol. 1990;7:229-241.
20. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother. 1990;34:1336-1341.
21. Matsui K, Masuda N, Takada M, et al. A randomized trial comparing imipenem/cilastatin alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn J Clin Oncol. 1991;21:428-434.
22. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J. 1991;10:918-923.
23. Leyland MI, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother. 1992;30:843-854.
24. Cornelissen JJ, deGraeff A, Verdonck F, et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients. Antimicrob Agents Chemother. 1992;36:801-807.
25. Bosseray A, Nicolini F, Brion JP, et al. [Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin]. Pathol Biol (Paris). 1992;40:797-804.
26. Huijgens PC, Ossenkoppele GJ, Weijers TF, et al. Imipenemcilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies. Eur J Haematol. 1991;46:42-46.
27. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995;13:165-176.
28. Winston DJ, Ho WG, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991;115:849-859.
29. Sanders CC. Cefepime: the next generation. Clin Infect Dis. 1993;17:369-379.
30. Klugman K, Goldstein F, Kohno S, et al. The role of fourth generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect. 1997;3:S48-S60.
31. Kessler RE, Fung-Tome J. Susceptibility of bacterial isolates to β-lactam antibiotics from USU clinical trials over a 5-year period. Am J Med. 1996;100:13S-19S.
32. Ramphal R, Gucalp R, Rotstein C, et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med. 1996;100:83S-89S.
33. Breen J, Ramphal R, Cometta A, et al. Cefepime versus ceftazidime as empiric therapy of febrile neutropenic patients. In: Klastersky J, editor. Febrile neutropenia. Berlin: Springer-Verlag, 1997:63-74.
34. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis. 1999;29:508-514.
35. Biron P, Fuhrmann C, Cure H, et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. J Antimicrob Chemother. 1998;42:511-518.
36. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999;29:503-507.
37. Elting LS, Khardori N, Bodey GP, et al. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990;11:134-138.